Assess whether biosimilarity is analytically justified (b323e6)

Situation

A mid-size sponsor after a complete response letter cannot treat an inspector asking for batch records you cannot produce this week as color commentary on 505(b)(2) literature-to-product bridge table. CMC change-control owner must close biosimilarity is analytically justified from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• CMC change-control owner can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week in a Pharma & Life Sciences challenge.
• CMC change-control owner cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after an inspector asking for batch records you cannot produce this week.
• An inspector asking for batch records you cannot produce this week never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close biosimilarity is analytically justified.
• Two facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week conflict for CMC change-control owner; hold this Pharmacovigilance file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against an inspector asking for batch records you cannot produce this week and write the one fact that would move biosimilarity is analytically justified for CMC change-control owner.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.